Wednesday, June 03, 2026 The 2026 #ASCO Annual Meeting will be held in Chicago this weekend from May 29 through June 2 with a range of abstracts from CCTG trials. Here is a list of the research that will be presented with abstract links - if you are attending make sure to stop by! BREASTCCTG MAC.30/NRG BR009 A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.Abstract:TPS650 Session Type: Poster Session Session Title:Breast Cancer—Local/Regional/AdjuvantCitation: J Clin Oncol 44, 2026 (suppl 16; abstr TPS650) Authors: Eleftherios Mamounas, Gong Tang, Shannon Puhalla, Sandra Swain, Patricia Ganz, Norah Henry, Reena Cecchini, Sonya Reid, Priya Rastogi, Charles Geyer Jr., Julia White, Amy Clark, Tufia Haddad, Gregory Vidal, Norman WolmarkAbstract link: https://www.asco.org/abstracts-presentations/266595GASTROINTESTINALCCTG CO.21Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trialAbstract #: 3507 Session Type: Oral Abstract Session Session Title: Gastrointestinal Cancer—Colorectal and AnalTrack: Gastrointestinal Cancer—Colorectal and AnalCitation: J Clin Oncol 44, 2026 (suppl 16; abstr 3507)Authors: Kelvin K. Chan, Ryan W. Chu, Matthew C. Cheung, Kerry S. Courneya, Christopher J. O'Callaghan, Janette L. Vardy. Sharlene Gill, Christine Friedenreich, Rebecca K. Wong, Haryana M. Dhillon, Vicky Coyle, Neil S. Chua, Derek J. Jonker, Ralph M. Meyer, Shahid Ahmed, John R. Zalcberg, Stephen J. Clarke, Patti O'Brien, Dongsheng Tu, Christopher M. BoothAbstract link: https://www.asco.org/abstracts-presentations/260675CCTG CO.33The CO.33/BATTMAN trial: A phase 3 randomized study of botensilimab + balstilimab versus best supportive care in chemorefractory unresectable colorectal adenocarcinoma that is not dMMR/MSI-H.Abstract #: TPS3676 Session Type: Poster Session Session Title:Gastrointestinal Cancer—Colorectal and AnalCitation: J Clin Oncol 44, 2026 (suppl 16; abstr TPS3676) Authors: Jonathan M. Loree, Jeanne Tie, Emmanuelle Samalin, Sharlene Gill, Benny Johnson, Joseph E. Grossman, Steven O'Day, Eric X. Chen, Christos S. Karapetis, Christelle De La Fouchardiere, Winson Y. Cheung, Kelvin K. Chan, Catherine Rutledge, Dongsheng Tu, Christopher J. O'CallaghanAbstract link: https://www.asco.org/abstracts-presentations/266856CCTG CO.26Serum VEGF-A concentrations as a predictive biomarker of immunotherapy response in refractory metastatic colorectal cancer (mCRC): An exploratory analysis of CCTG CO.26Abstract #: 3547 Session Type: Poster Session Session Title: Gastrointestinal Cancer—Colorectal and AnalCitation: J Clin Oncol 44, 2026 (suppl 16; abstr 3547)Authors: François Jobin Gervais, Xin Wang, Jonathan M. Loree, Emma Titmuss, Trevor J. Pugh, Derek J. Jonker, Hagen F. Kennecke, Scott Berry, Aaron R. Hansen, Philippe Bedard, Stephanie Lheureux, Anna Spreafico, Albiruni R. Abdul Razak, Lillian L. Siu, Felix Couture, Ahmad Chaudhary, John R. Goffin, Dongsheng Tu, Christopher J. O'Callaghan, Eric X. ChenAbstract link: https://www.asco.org/abstracts-presentations/262550CCTG CRC.6/CALGB/SWOG 80702Lycopene and survival in patients with stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702Abstract #: 3630 Session Type: Poster Session Session Title: Gastrointestinal Cancer—Colorectal and Anal Citation: J Clin Oncol 44, 2026 (suppl 16; abstr 3630)Authors: Seohyuk Lee, Qian Shi, Chao Ma, Pankaj Kumar, Felix Couture, J. P. Kuebler, Smitha S. Krishnamurthi, Benjamin R. Tan, Eileen M. O'Reilly, Anthony F. Shields, Edward L. Giovannucci, Yasmin Mossavar-Rahmani, Jeffrey A. Meyerhardt, En ChengAbstract link: https://www.asco.org/abstracts-presentations/262239CCTG CRC.10/NRG GI008Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.Abstract #: TPS3686Session Type: Poster SessionSession Title: Gastrointestinal Cancer—Colorectal and AnalCitation: J Clin Oncol 44, 2026 (suppl 16; abstr TPS3686) Authors: Arvind Dasari, Guan Yu, Scott Kopetz, Shannon Puhalla, Peter Lucas, Ibrahim Halil Sahin, Dustin Deming, Philip Philip, Theodore Hong, Yesenia Rojas-Khalil, Jonathan Loree, Norman Wolmark, Greg Yothers, Thomas George, Christopher LieuAbstract link: https://www.asco.org/abstracts-presentations/266852GENITOURINARY CCTG GCC1/SWOG S1823First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.Abstract #: LBA5003 Session Type: Oral Abstract Session Session Title: Genitourinary Cancer—Prostate, Testicular, and PenileCitation: J Clin Oncol 44, 2026 (suppl 17; abstr LBA5003) Authors: Lucia Nappi, Sarah Colby, Robert W. Hamilton, Andrea Harzstark, Nabil Adra, Siamak Daneshmand, Christopher W. Ryan, Scott E. Eggener, Chunkit Fung, Rebecca Johnson, Seth P. Lerner, Kathryn B. Arnold, Banu Arun, James M. Rae, Charles D. Blanke, Michael LeBlanc, Wendy R. Parulekar, Lawrence H. Einhorn, Christian K. Kollmannsberger, Craig R. NicholsAbstract link: https://www.asco.org/abstracts-presentations/260571 CCTG PR.21Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO): Results of crossover treatment from a randomized trial of 177Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC).Abstract #: 5019 Session Type: Rapid Oral Abstract Session Session Title: Genitourinary Cancer—Prostate, Testicular, and PenileCitation: J Clin Oncol 44, 2026 (suppl 16; abstr 5019) Authors: Kim N. Chi, Fred Saad, Keyue Ding, Glenn Bauman, Urban Emmenegger, Sebastien J. Hotte, Frederic Pouliot, Justin Lee, Jean-Mathieu Beauregard, Lucia Nappi, Christian K. Kollmannsberger, Zineb Hamilou, Gad Abikhzer, Michel Pavic, Scott A. North, Di Maria Jiang, Steven Yip, Conor Dellar, Wendy R. Parulekar, Francois BenardAbstract link: https://www.asco.org/abstracts-presentations/258188/abstractCCTG PR25A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225.Abstract #: TPS5143Session Type: Poster SessionSession Title: Genitourinary Cancer—Prostate, Testicular, and PenileTrack: Genitourinary Cancer—Prostate, Testicular, and Penile Citation: J Clin Oncol 44, 2026 (suppl 16; abstr TPS5143)Authors: Michael Ong, Michael P. Kolinsky, Kim N. Chi, Sebastien J. Hotte, Michael D. Brundage, Daniel J. Khalaf, David Boren, M. N. Reaume, Alexander W. Wyatt, Wendy R. Parulekar, Keyue Ding, Mariam JafriAbstract link: https://www.asco.org/abstracts-presentations/266929CCTG PR.26TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).Abstract #: TPS5129Session Type: Poster SessionSession Title: Genitourinary Cancer—Prostate, Testicular, and PenileTrack: Genitourinary Cancer—Prostate, Testicular, and PenileCitiation: J Clin Oncol 44, 2026 (suppl 16; abstr TPS5149)Authors: Michael Ong, Alexandra Sokolova, Sebastien Hotte, Tanya Dorff, Kim Chi, Alexander Wyatt, Amir Goldkorn, Michael Kolinsky, Michael Brundage, Akunne Ndika, Seth Lerner, Wendy Parulekar, Keyue Ding, Mariam JafriAbstract link: https://www.asco.org/abstracts-presentations/266930CCTG PRC.4/Alliance A031201Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201.Abstract #: 5018 Session Type: Rapid Oral Abstract Session Session Title: Genitourinary Cancer—Prostate, Testicular, and PenileCitiation: J Clin Oncol 44, 2026 (suppl 16; abstr 5018)Abstract link: https://www.asco.org/abstracts-presentations/259369 CCTG REC.4/EA8143Relationships between clinical stage, pathological stage, and disease-free (DFS) survival in renal cell carcinoma as used to inform future neoadjuvant study design: ECOG-ACRIN EA8143 PROSPER analysis.Abstract #: 4540 Session Type: Poster Session Session Title: Genitourinary Cancer—Kidney and BladderCitiation: J Clin Oncol 44, 2026 (suppl 16; abstr 4540)Authors: James O. Jones, Se E. Kim, Mohamad E. Allaf, Viraj A. Master, David F. McDermott, Sabina Signoretti, Axel Bex, Grant D. Stewart, James Blackmur, Nirmish Singla, Nabil Adra, Stephanie A. Berg, Dror Michaelson, Daniel Y. Heng, Brian M. Shuch, Yasser Ged, Mehmet A. Bilen, Gennady Bratslavsky, Michael A. Carducci, Naomi B. HaasAbstract link: https://www.asco.org/abstracts-presentations/262634 GYNECOLOGIC CANCER CCTG ENC.1/NRG-GY018Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial).Abstract #: 5502 Session Type: Oral Abstract Session Session Title: Gynecologic CancerCitation: J Clin Oncol 44, 2026 (suppl 16; abstr 5502)Authors: Ramez N. Eskander, Michael Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, Guilherme H. Cantuaria, Eugenia Girda, Cara A. Mathews, Juraj Kavecansky, Charles A. Leath III, Lilian T. Gien, Emily Hinchcliff, Shashikant B. Lele, Lisa M. Landrum, Floor J. Backes, Matthew A. Powell, Carol AghajanianAbstract link: https://www.asco.org/abstracts-presentations/258036 HEAD AND NECK CANCER CCTG HN.9Final analysis of the investigator-initiated randomized study of anti–PD-L1 durvalumab (durva) with radiation versus chemoradiation (CRT) for intermediate-risk HPV-positive (HPV+) locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC): Canadian Cancer Trials Group (CCTG) HN.9 (EORTC 1740-HNCG).Abstract #: 6017Session Type: Rapid Oral Abstract SessionSession Title: Head and Neck CancerCitation: J Clin Oncol 44, 2026 (suppl 16; abstr 6017) Authors: Anna Spreafico, Khalil Sultanem, Jean-Pascal H. Machiels, Scott V. Bratman, John Hilton, Lisa F. Licitra, Alexander V. Louie, Andrea McNiven, Jolie Ringash, Lillian L. Siu, John Waldron, Osama Souied, Andrew G. Robinson, Changshu Wang, Craig H. Harlos, Marc Oliva, John W. Walker, Kate Whelan, Wei Tu, Wendy R. ParulekarAbstract link: https://www.asco.org/abstracts-presentations/260979 LUNG/THORACIC ONCOLOGY CCTG BR.34Effect of dual immune checkpoint inhibitors (ICI) by the time of infusion in advanced non–small cell lung cancer (NSCLC): A secondary analysis of CCTG BR34 trialAbstract #: 8566Session Type: Poster SessionSession Title: Lung Cancer – Non-Small Cell MetastaticTrack: Lung CancerCitation: J Clin Oncol 44, 2026 (suppl 16; abstr 8566)Authors: Sze Wah Samuel Chan, Adi Kartolo, Keyue Ding, Pierre-Olivier Gaudreau, Rosalyn A. Juergens, Natasha B. Leighl, Janet E. DanceyAbstract link: https://www.asco.org/abstracts-presentations/265945 CCTG BR.38CCTG BR.38: Consolidative use of radiotherapy to block (CURB2) oligoprogression in patients with metastatic non–small-cell lung cancer—A randomized phase III trial.Abstract #: TPS81248566Session Type: Poster SessionSession Title: Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic CancersTrack: Lung CancerCitation: J Clin Oncol 44, 2026 (suppl 16; abstr TPS8124)Authors: Chiaojung Jillian Tsai, Alexander Sun, Penelope A. Bradbury, Devin Schellenberg, Houda Bahig, Andrea S. Fung, Jean-Pierre Bissonnette, Jeeban Paul Das, Biniam Kidane, Alexander V. Louie, Joseph Miccio, Meng X. Welliver, John M. Varlotto, Arya Amini, Ryan Kelly, Keyue Ding, Pierre-Olivier GaudreauAbstract link: https://www.asco.org/abstracts-presentations/266720
